Drug Patent Expirations for Jan 22 2012

January 27, 2012

in Biotechnology Industry News

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,895 Subscribe$1,695 Subscribe$975 Subscribe
One month$475 Subscribe$375 Subscribe$275 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Jan 22 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
VIDEXBristol Myers Squibbdidanosine5,880,106*PEDJan 22, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Tentative Approvals

IngredientTentative Approvals
didanosine1

*Tentative approvals are indicators of potential future generic entry. See the DrugPatentWatch database for complete details.


The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Comments on this entry are closed.

Previous post:

Next post: